BN82002 is a cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. BN82002 inhibits the phosphatase activity of recombinant human CDC25A, B, and C in vitro. It impairs the proliferation of tumoral cell lines and increases cyclin-dependent kinase 1 inhibitory tyrosine phosphorylation. BN82002 delays cell cycle progression at G1-S, in S phase and at the G2-M transition in synchronized HeLa cells.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO ≥ 60 mg/mL|
CDC25 Inhibition in Acute Myeloid Leukemia-A Study of Patient Heterogeneity and the Effects of Different Inhibitors.
Brenner AK, et al. Molecules. 2017 Mar 11;22(3). PMID: 28287460.
A novel synthetic inhibitor of CDC25 phosphatases: BN82002.
Brezak MC, et al. Cancer Res. 2004 May 1;64(9):3320-5. PMID: 15126376.
|Related Phosphatase Products|
KY-226 is a protein tyrosine phosphatase 1B (PTP1B) inhibitor with IC50 of 0.25 μM, which protects neurons from cerebral ischemic injury.
BTdCPU is an potent activator of HRI, it promotes eIF2α phosphorylation and induced apoptosis in resistant cell.
F1063-0967 is a novel inhibitor of dual-specificity phosphatase 26 (DUSP26), inducing apoptosis in IMR-32 cell line.
TPI-1 is a SHP-1 inhibitor, inhibits recombinant SHP-1 with an IC50 of 40 nM.
RMC-4550 is a potent and selective SHP2 inhibitor, with an IC50 of 0.583 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.